FDA Brief

Warning letters Biologics

FDA warning letter to

Dynamic Stem Cell Therapy

High riskIssued Feb 11Posted Feb 24Center for Biologics Evaluation and Research

FDA warned Dynamic Stem Cell Therapy that its umbilical cord-derived stem cell product is an unapproved, unlicensed, misbranded biological drug.

What happened

FDA reviewed the company’s website at stemcellpowernow.com in February 2026; the letter does not describe an inspection. FDA found claims that the umbilical cord-derived stem cell product treats sports injuries, arthritis, cardiovascular disease, and other conditions. FDA said the product is an unapproved drug and unlicensed biological product, failed human cell/tissue product criteria, was misbranded for lacking adequate directions, and also noted the company markets exosomes.

What FDA found

  1. FDA said the product is a drug and biological product because the website claims it treats diseases or affects body structure or function.

    FD&C Act section 201(g)(1), 21 U.S.C. § 321(g)(1); PHS Act section 351(i), 42 U.S.C. § 262(i)
  2. FDA said processing the umbilical cord into an injectable form more than minimally manipulates it, so it does not qualify for the human cell/tissue product exception.

    21 CFR 1271.10(a)(1); 21 CFR 1271.3(f)(1)
  3. FDA said the product is promoted for uses like arthritis and cardiovascular disease, not the umbilical cord’s basic conduit function, so it fails the homologous-use criterion.

    21 CFR 1271.10(a)(2); 21 CFR 1271.3(c)
  4. FDA said the product lacks adequate directions for safe use by a layperson because it is for diseases that require a licensed practitioner.

    FD&C Act section 502(f)(1), 21 U.S.C. § 352(f)(1); 21 CFR 201.5
  5. FDA said the product is not covered by an approved biologics license application (BLA), the approval needed to show a biologic is safe, pure, and potent.

    PHS Act section 351(a)(1), 42 U.S.C. § 262(a)(1)
  6. FDA said selling the misbranded product after shipment in interstate commerce violates the FD&C Act.

    FD&C Act section 301(k), 21 U.S.C. § 331(k)

What FDA wants

FDA asks the company to submit a written response within 15 working days outlining specific steps taken or planned to address the violations and prevent recurrence, with supporting documentation. If the company cannot meet that timeframe, FDA asks for the reason for delay and a completion timeframe; if it disagrees, FDA asks for its reasoning and supporting information.

Who should pay attention

  • clinics offering regenerative or stem cell treatments
  • companies marketing umbilical cord-derived or exosome products
  • buyers and suppliers of birth tissue-derived products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Beaute Bounty

    FDA warns Beaute Bounty that its stem cell and placenta products are unapproved drugs and unlicensed biologics.

    High risk